Table 1.
Demographic and clinical data for patients surviving ARDS.
| Parameter | COVID-19 n = 64 |
Non-COVID n = 30 |
T-test or Chi-square, p = 0.05 |
|---|---|---|---|
| Age, years, mean ± SD | 54 ± 13 | 50 ± 13 | p = 0.14 |
| Male, n (%) | 32 (50) | 16 (53) | p = 0.77 |
| Race/ethnicity | |||
| Caucasian/White, n (%) | 48 (75) | 30 (100) | p = 0.002A |
| African America/Black, n (%) | 9 (14) | 0 (0) | |
| Other, n (%) | 7 (11) | 0 (0) | |
| Tobacco use | |||
| Current, n (%) | 10 (16) | 13 (43) | p = 0.38B |
| Former, n (%) | 19 (30) | 5 (17) | |
| Never, n (%) | 33 (52) | 12 (40) | |
| Body mass index (kg/m2), mean ± SD | 35.9 ± 8.4 | 32.6 ± 8.3 | p = 0.046 |
| Charlson comorbidity index | 2.7 ± 1.9 | 2.6 ± 2.1 | p = 0.85 |
| Chronic lung disease, n (%) | 10(16) | 11 (37) | p = 0.033 |
| SOFA, mean ± SD | 11.3 ± 2.5 | 10.7 ± 2.6 | p = 0.34 |
| MV, yes, % | 64 (100) | 30 (100) | |
| MV duration, mean ± SD | 17.3 ± 12.4 | 15.1 ± 11.2 | p = 0.33 |
| Oxygenation (HFNC + MV) days, mean ± SD | 20.8 ± 12.6 | 16.2 ± 11.4 | p = 0.048 |
| FiO2 (peak 72 h), mean ± SD | 90.9 ± 14.3 | 78.8 ± 22.5 | p = 0.009 |
| PEEP (peek 72 h), mean ± SD | 13.6 ± 3.2 | 11.5 ± 4.4 | p = 0.030 |
| Tracheostomy, n (%) | 24 (38) | 14 (47) | p = 0.40 |
| ECMO, n (%) | 9 (14) | 4 (13) | p = 0.92 |
| CRRT, n (%) | 9 (14) | 4 (13) | p = 0.92 |
| Steroids, n (%) | 58 (91) | 16 (53) | p < 0.001 |
| Vasopressor/inotropes, n (%) | 45 (70) | 19 (63) | p = 0.50 |
| NMB, n (%) | 24(38) | 9 (30) | p = 0.48 |
| RASS (mean 72 h), mean ± SD | − 3.4 ± 1.2 | − 2.9 ± 1.5 | p = 0.16 |
| COVID-19 therapies | |||
| Hydroxychloroquine | 5 (8) | ||
| Tocilizumab | 14 (22) | ||
| Remdesivir | 38 (59) | ||
| Convalescent plasma | 11 (17) | ||
| ICU LOS | 23.2 ± 14.8 | 20.9 ± 13.9 | p = 0.394 |
| Hospital LOS | 33.8 ± 17.6 | 26.9 ± 15.5 | p = 0.09 |
| Discharge destination | |||
| LTAC | 5 (8) | 9 (30) | |
| Acute | 36 (56) | 6 (20) | p = 0.26C |
| Home with HH | 12 (19) | 6 (20) | |
| Home | 11 (17) | 9 (30) | |
SOFA sequential organ failure assessment, MV mechanical ventilation, FiO2 fraction of inspired oxygen, PEEP positive end expiratory pressure, ECMO extracorporeal membrane oxygenation, AKI acute kidney injury, CRRT continuous renal replacement therapy, NMB neuromuscular blocker, RASS Richmond Agitation Sedation Scale.
AFisher’s exact test assessing Caucasian/White vs combined African American/Black and Other.
BFisher’s exact test assessing combined Current and Former vs Never tobacco use.
CFisher’s exact test comparing discharge to Home + Home with HH compared to discharge to facility (acute + LTAC).